Literature DB >> 32009106

Toxicological Property of Acetaminophen: The Dark Side of a Safe Antipyretic/Analgesic Drug?

Yoichi Ishitsuka1, Yuki Kondo1, Daisuke Kadowaki2.   

Abstract

Acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) is the most popular analgesic/antipyretic agent in the world. APAP has been regarded as a safer drug compared with non-steroidal anti-inflammatory drugs (NSAIDs) particularly in terms of lower risks of renal dysfunction, gastrointestinal injury, and asthma/bronchospasm induction, even in high-risk patients such as the elderly, children, and pregnant women. On the other hand, the recent increasing use of APAP has raised concerns about its toxicity. In this article, we review recent pharmacological and toxicological findings about APAP from basic, clinical, and epidemiological studies, including spontaneous drug adverse events reporting system, especially focusing on drug-induced asthma and pre-and post-natal closure of ductus arteriosus. Hepatotoxicity is the greatest fault of APAP and the most frequent cause of drug-induced acute liver failure in Western countries. However, its precise mechanism remains unclear and no effective cure beyond N-acetylcysteine has been developed. Recent animal and cellular studies have demonstrated that some cellular events, such as c-jun N-terminal kinase (JNK) pathway activation, endoplasmic reticulum (ER) stress, and mitochondrial oxidative stress may play important roles in the development of hepatitis. Herein, the molecular mechanisms of APAP hepatotoxicity are summarized. We also discuss the not-so-familiar "dark side" of APAP as an otherwise safe analgesic/antipyretic drug.

Entities:  

Keywords:  acetaminophen (APAP); drug-induced asthma; ductus arteriosus; endoplasmic reticulum stress; hepatotoxicity; mitochondria

Mesh:

Substances:

Year:  2020        PMID: 32009106     DOI: 10.1248/bpb.b19-00722

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

Review 1.  COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

Authors:  Dâmaris Silveira; Jose Maria Prieto-Garcia; Fabio Boylan; Omar Estrada; Yris Maria Fonseca-Bazzo; Claudia Masrouah Jamal; Pérola Oliveira Magalhães; Edson Oliveira Pereira; Michal Tomczyk; Michael Heinrich
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

2.  Adrenergic blocker terazosin potentially suppresses acetaminophen induced-acute liver injury in animal models via CYP2E1 gene.

Authors:  Zoya Hashmat; Iffat Saeed Channa; Muhammad Safdar; Mehmet Ozaslan; Muhammad Saeed; Faisal Siddique; Yasmeen Junejo
Journal:  Toxicol Res       Date:  2022-01-11

3.  Protective Effects of Polydatin from Grapes and Reynoutria japonica Houtt. on Damaged Macrophages Treated with Acetaminophen.

Authors:  Can Liu; Wenyi Wang; Kaixin Zhang; Qiudi Liu; Tongyao Ma; Li Tan; Lanqing Ma
Journal:  Nutrients       Date:  2022-05-16       Impact factor: 6.706

Review 4.  The Involvement of Caspases in Neuroinflammation and Neuronal Apoptosis in Chronic Pain and Potential Therapeutic Targets.

Authors:  Haoyue Zhang; Nan Li; Ziping Li; Yize Li; Yonghao Yu; Linlin Zhang
Journal:  Front Pharmacol       Date:  2022-05-03       Impact factor: 5.988

5.  Hepatoprotective Effects of Crude Stem Bark Extracts and Solvent Fractions of Cordia africana against Acetaminophen-Induced Liver Injury in Rats.

Authors:  Gudeta Duga Geresu; Shemsu Umer; Mahlet Arayaselassie; Genet Ashebir; Eyasu Makonnen
Journal:  Can J Gastroenterol Hepatol       Date:  2022-03-29

6.  FTY720 attenuates APAP‑induced liver injury via the JAK2/STAT3 signaling pathway.

Authors:  Xiangmin He; Kai Kang; Dan Pan; Yue Sun; Bing Chang
Journal:  Int J Mol Med       Date:  2022-03-18       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.